๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

CT studies before and after CNS treatment for acute lymphoblastic leukemia and malignant non-Hodgkin's lymphoma in childhood

โœ Scribed by K. Kretzschmar; P. Gutjahr; J. Kutzner

Publisher
Springer
Year
1980
Tongue
English
Weight
894 KB
Volume
20
Category
Article
ISSN
0028-3940

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Results of a BFM-based protocol for the
Results of a BFM-based protocol for the treatment of childhood B-non-Hodgkin's lymphoma and B-Acute lymphoblastic leukemia in Argentina
โœ Chantada, Guillermo Luis; Felice, Maria Sara; Zubizarreta, Pedro Alberto; Diaz, ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 135 KB ๐Ÿ‘ 3 views

## Purpose: To report the feasibility and results of a study based on the bfm-all. nhl/86 protocol for b-non-hodgin's lymphoma (nhl) and b-acute lymphoblastic leukemia (b-all) in argentina. design. prospective, single arm, non-randomized trial. ## Patients and methods: From august 1988 to decembe

Improvement in CNS protective treatment
Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group
โœ Tsurusawa, Masahito; Katano, Naoyuki; Yamamoto, Yoshifumi; Hirota, Takahisa; Koi ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 126 KB ๐Ÿ‘ 3 views

Background. Prevention of central nervous system (CNS) leukemia by early introduction of therapy to this sanctuary site is an essential component of modern treatment strategy for acute lymphoblastic leukemia (ALL). However, the optimal form of preventive CNS therapy remains debatable. Procedure. To

Acute promyelocytic leukemia after treat
Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II
โœ De Renzo, A.; Santoro, L.F.E.; Notaro, R.; Pane, F.; Buonaiuto, M.R.; Luciano, L ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 201 KB ๐Ÿ‘ 2 views

We report a patient who developed acute promyelocytic leukemia (APL) concomitantly with a second relapse of non-Hodgkin's lymphoma (NHL), intermediate grade, WF type E. At diagnosis and at first NHL relapse, the patient had received the same chemotherapy regimen, which included drugs targeting DNA t